Is Sermorelin Legal in Oregon?

The Short Answer on Sermorelin's Legal Status in Oregon

Sermorelin is legal to prescribe, dispense, and possess in Oregon. It is not a controlled substance, and no Oregon statute specifically restricts it beyond the standard prescription-drug framework that applies to all legend drugs. The practical legal question is not whether sermorelin itself is banned, but whether the pharmacy compounding it and the provider prescribing it are operating inside the applicable federal and state rules.

Oregon follows the federal compounding framework established under the Drug Quality and Security Act of 2013, which created two compounding categories: 503A (traditional, patient-specific) and 503B (outsourcing facilities, larger-scale) [1]. Both pathways are lawful in Oregon, provided the compounding pharmacy holds an active Oregon Board of Pharmacy (OBP) license and meets good manufacturing standards.

Federal Legal Framework: Why Sermorelin Is Unscheduled

Sermorelin Is Not a Controlled Substance

The Drug Enforcement Administration (DEA) schedules substances under the Controlled Substances Act (CSA). Sermorelin does not appear on any DEA schedule [2]. It is not an anabolic steroid, a stimulant, or a narcotic. Possession without a prescription by an individual is not a federal criminal offense in the same category as Schedule II, V substances, though dispensing it without a prescription remains illegal under the Federal Food, Drug, and Cosmetic Act (FD&C Act) [3].

The 2008 Market Withdrawal and What It Means

Sermorelin acetate (brand name Geref, manufactured by Serono) held FDA approval for growth hormone deficiency in children. The manufacturer voluntarily withdrew it from the commercial market in 2008. That withdrawal was a business decision, not an FDA enforcement action [4]. The withdrawal does not make sermorelin illegal. It does, however, mean the drug is no longer available as an FDA-approved finished product, which is why compounding pharmacies are now the only lawful source.

FDA Bulk Drug Substances List

The FDA regulates which active pharmaceutical ingredients (APIs) compounding pharmacies may use. Under Section 503A, a compounder may use a bulk drug substance that appears on the FDA's 503A Bulks List (the "positive list") or that has been nominated for evaluation and is not yet prohibited [5]. Sermorelin has been used in compounding for years under this framework. Prescribers and patients should verify with their specific pharmacy that the API lot used is sourced from an FDA-registered facility, as substandard raw material is the most common compliance failure in peptide compounding.

Oregon State Legal Framework

Oregon Board of Pharmacy (OBP) Rules

The Oregon Board of Pharmacy licenses and regulates all pharmacies dispensing to Oregon residents, including out-of-state mail-order compounders [6]. For a compounded sermorelin product to be dispensed legally in Oregon:

• The compounding pharmacy must hold an active OBP license (or a non-resident pharmacy permit if operating from another state).
• The prescription must be patient-specific if the pharmacy operates under 503A.
• A 503B outsourcing facility may ship to Oregon providers without a patient-specific prescription, but the dispensing provider must still issue a prescription before administration.

Oregon Revised Statutes Chapter 689 governs pharmacy practice and does not single out sermorelin or any other peptide by name [6]. The OBP has not issued any guidance specifically restricting sermorelin as of the date of this article's review.

Oregon Medical Practice Act

The Oregon Medical Practice Act (ORS Chapter 677) governs physician prescribing. Any drug prescribed must be issued for a legitimate medical purpose within the provider's scope of practice and following a valid patient-provider relationship [7]. Prescribing sermorelin for documented growth hormone deficiency or clinically supported age-related GH insufficiency generally falls within the scope of internal medicine, endocrinology, and anti-aging or functional medicine practice. Prescribing without a clinical evaluation, lab work, or documented indication could expose a provider to Oregon Medical Board scrutiny regardless of the drug's scheduling status.

No Oregon-Specific Sermorelin Statute

No Oregon law specifically names sermorelin as a prohibited or restricted substance beyond the standard legend-drug prescription requirement. This contrasts with anabolic steroids, which have explicit state-level scheduling. Patients and providers should not confuse the absence of Oregon-specific sermorelin legislation with a "free zone." Federal FDA and DEA rules still apply to everyone in Oregon.

How to Get Sermorelin Legally in Oregon

The following four-step pathway reflects how a patient in Oregon can obtain sermorelin legally and safely.

Step 1: Establish Care With a Licensed Oregon Provider

The first requirement is a valid prescription from a provider licensed in Oregon. Eligible prescribers include MDs, DOs, nurse practitioners (NPs) with prescriptive authority, and physician assistants (PAs) practicing under Oregon's scope-of-service rules. Telehealth consultations with Oregon-licensed providers are permitted. The provider must conduct a clinical evaluation that includes relevant history and, in most cases, laboratory assessment.

Step 2: Get the Right Lab Work

Before prescribing sermorelin, a responsible provider will typically order:

• IGF-1 (insulin-like growth factor 1): The primary surrogate marker for growth hormone secretion. The Endocrine Society's 2011 Clinical Practice Guideline on adult growth hormone deficiency recommends IGF-1 as the initial biochemical screen [8].
• GH stimulation testing (optional but common): A confirmed GH deficiency diagnosis often requires an arginine or glucagon stimulation test per Endocrine Society standards [8].
• Baseline metabolic panel, CBC, thyroid function: To exclude confounding conditions affecting GH secretion.

An IGF-1 in the lower quartile for age and sex, combined with consistent symptoms (fatigue, reduced lean mass, increased visceral adiposity, impaired sleep), typically supports clinical prescribing.

Step 3: Obtain the Prescription From an OBP-Licensed Compounding Pharmacy

After the provider writes the prescription, it is sent to a compounding pharmacy. The pharmacy must:

• Hold an active OBP license or a valid Oregon non-resident pharmacy permit.
• Source sermorelin API from an FDA-registered manufacturer.
• Compound under USP <795> (non-sterile) or USP <797> (sterile injectable) standards. Injectable sermorelin requires USP <797> compliance [9].
• Label the product with the patient name, prescriber name, directions, and beyond-use date per OBP rule.

Step 4: Follow the Prescribed Protocol

Most sermorelin protocols call for 0.2 to 0.3 mg (200 to 300 mcg) subcutaneous injection administered nightly, roughly 30 minutes before sleep, to coincide with the body's natural nocturnal GH pulse [10]. The prescriber should schedule follow-up IGF-1 testing at 3 months to assess response and adjust dosing.

Clinical Evidence Supporting Sermorelin Use

Growth Hormone Physiology and GHRH Analogues

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). It binds pituitary GHRH receptors and stimulates pulsatile GH secretion rather than replacing GH directly. This indirect mechanism is considered an advantage by many clinicians because it preserves the pituitary feedback loop, reducing the risk of the suppressive effects seen with exogenous recombinant GH [10].

Key Clinical Data

A randomized, double-blind, placebo-controlled trial by Vittone et al. (N=89 healthy men aged 65 to 88) found that 26 weeks of nightly sermorelin acetate (0.5 mg subcutaneous) increased IGF-1 by a mean of 55 micrograms/L versus placebo (P<0.001), with improvements in sleep quality and lean body mass [11]. The FDA approved the original Geref indication based on demonstrable GH secretagogue activity in pediatric GH deficiency, confirming the mechanism is clinically validated [4].

Adult GH deficiency itself carries significant metabolic burden. The Endocrine Society's 2011 guideline notes that adults with confirmed GH deficiency have increased cardiovascular risk, reduced bone mineral density, and impaired quality of life, and that GH replacement (and by extension, GH secretagogue therapy) is indicated when deficiency is confirmed [8].

A 2019 review published in Frontiers in Endocrinology examining GHRH analogues in aging populations found that sermorelin and related peptides produced consistent IGF-1 elevation and lean mass improvements with a favorable safety profile compared to direct GH administration, though the authors noted that large-scale, long-duration randomized controlled trials remain limited [12].

Safety Profile

The most common adverse effects in clinical trials were injection-site reactions (mild erythema in approximately 17% of patients), transient flushing, and headache [11]. Sermorelin does not appear to suppress endogenous GH production after discontinuation, in contrast to exogenous rhGH [10]. No cases of sermorelin-induced malignancy have been reported in controlled studies, though standard oncology precautions apply: active malignancy is a contraindication to any GH secretagogue therapy per Endocrine Society guidance [8].

Risks of Obtaining Sermorelin Outside the Legal Pathway

Patients occasionally encounter sermorelin sold online without a prescription, sometimes labeled "for research use only." Purchasing or possessing such products carries meaningful risks.

• Regulatory risk: The FD&C Act prohibits dispensing prescription drugs without a valid prescription [3]. An online vendor selling sermorelin without requiring a prescription is violating federal law. The buyer is not typically prosecuted, but the product quality is unverifiable.
• Quality risk: The FDA's Division of Drug Quality has issued multiple warning letters to compounders and online vendors for subpotent, contaminated, or mislabeled peptide products [13]. A 2021 FDA analysis of compounded peptide samples found that a meaningful proportion failed potency specifications.
• Clinical risk: Using sermorelin without baseline labs and provider supervision means dosing is essentially guesswork. Excessive GH stimulation may worsen insulin resistance or cause fluid retention.

The safe and legal route is straightforward in Oregon: get a prescription, use an OBP-licensed pharmacy, and test IGF-1 before and after starting treatment.

Telehealth Prescribing of Sermorelin in Oregon

Oregon permits telehealth prescribing of non-controlled substances, including sermorelin, provided the prescribing clinician holds an active Oregon license and conducts a clinically appropriate evaluation [7]. Under Oregon's telehealth rules aligned with ORS 677.060, a valid patient-provider relationship can be established via synchronous video consultation [7].

Patients using a telehealth platform to access sermorelin should confirm:

1. The prescribing provider is licensed in Oregon (verify at the Oregon Medical Board's public lookup tool).
2. The pharmacy dispensing the product holds an OBP license (verify at the OBP license search).
3. Lab work is ordered before initiation, not skipped for convenience.

Telehealth platforms that skip lab work entirely, charge flat subscription fees without clinical evaluation, or ship sermorelin before a consultation should be treated as red flags for regulatory non-compliance.

Sermorelin vs. Other Peptides: Why Legal Status Differs

Not all growth hormone secretagogues share sermorelin's legal standing. Ipamorelin, CJC-1295, and BPC-157 occupy a more complex regulatory position. The FDA placed several peptides on its "Category 2" list of bulk drug substances that may not be used in compounding under 503A because they raise safety concerns or lack adequate evidence [5]. Sermorelin is not on the Category 2 prohibition list as of this article's review date, which is why its compounding pathway remains open.

Patients interested in peptide therapy should verify the current FDA bulk drug substance status of any specific peptide with their provider, as the FDA updates these lists periodically and the regulatory environment for peptides has tightened since 2023 [5].

What Oregon Providers Are Prescribing Sermorelin For

The most documented clinical indications include:

• Confirmed adult growth hormone deficiency diagnosed by stimulation testing per Endocrine Society criteria [8].
• Age-related GH decline (somatopause), where IGF-1 falls below age-adjusted reference ranges and the patient has consistent symptoms.
• Body composition optimization in patients with documented GH insufficiency, typically combined with exercise and dietary intervention.
• Sleep quality improvement, supported by the known relationship between GH pulsatility and slow-wave sleep architecture [10].

Off-label use for anti-aging or general wellness without documented GH deficiency is practiced by some functional medicine providers. This is not prohibited by Oregon law, but the Oregon Medical Board expects a documented clinical rationale, lab support, and informed consent for any off-label prescribing [7].